Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Association between the myeloperoxidase gene polymorphisms and the susceptibilit...
Journal Information
Vol. 37. Issue 2.
Pages 79-82 (February 2013)
Share
Share
Download PDF
More article options
Visits
813
Vol. 37. Issue 2.
Pages 79-82 (February 2013)
Original article
Association between the myeloperoxidase gene polymorphisms and the susceptibility to prostate cancer: A case–control study in a Chinese population
Asociación entre los polimorfismos de genes de mieloperoxidasa y la susceptibilidad a cáncer de próstata: un estudio caso-control en la población de nacionalidad china
Visits
813
G. Dinga, F. Liua, C. Fenga, J. Xua,b, Q. Dinga,
Corresponding author
drdingqiang@163.com

Corresponding author.
a Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
b Department of Urology, Wake Forest University School of Medicine, Winston-Salem, Carolina del Norte, United States
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Associations between SNPs of MPO and prostate-cancer risk.
Abstract
Background and objectives

Prostate cancer (PCa) is the most common cancer among men in most western populations. The polymorphisms of the myeloperoxidase (MPO) gene have been correlated with abnormal MPO expression and increased risk of various types of cancers. Our study aimed to evaluate the association between the genetic polymorphisms and the risk of prostate cancer.

Methods

Genotyping was carried out by using the genotyping system (MassARRAY iPLEX; Sequenom, Inc., San Diego, CA, USA) on 1,108 PCa patients and 1,525 cancer-free controls in a Chinese Han population.

Results

Although one SNP (rs8082134, P<0.050) was significant, it is very rare and unstable. Other SNPs had no significant difference between genotype distributions in the PCa patients and the control group. Totally, SNPs in the MPO gene is not associated with PCa risk.

Conclusion

Our data showed a limited association between the MPO SNPs and the susceptibility to PCa in population of Chinese Han population. The possible association of rs8082134 of MPO with PCa risk need further clarification.

Keywords:
Myeloperoxidase
Polymorphism
Prostate cancer
Susceptibility
Resumen
Antecedentes y objetivos

El cáncer de próstata (CaP) es el cáncer más común entre los hombres en la mayoría de las poblaciones occidentales. El gen de polimorfismos de la mieloperoxidasa (MPO) se ha correlacionado con la expresión anormal de la MPO y el aumento del riesgo de varios tipos de cáncer. Nuestro estudio ha tenido como objetivo evaluar la asociación entre los polimorfismos genéticos y el riesgo de cáncer de próstata.

Métodos

La genotipificación se realizó mediante el sistema de genotipificación (MassARRAY IPLEX; Sequenom, Inc., San Diego, CA, EE. UU.) en 1.108 pacientes con CaP y 1.525 controles sin cáncer en una población china Han.

Resultados

Aunque un PNS (rs8082134, p < 0,050) fue significativo, es muy poco común e inestable. Otros PNS no tuvieron diferencias significativas entre las distribuciones de los genotipos en los pacientes con CaP y el grupo control. En total, los PNS en el gen de la MPO no se asocian con el riesgo de CaP.

Conclusión

Nuestros datos mostraron una asociación limitada entre los PNS de la MPO y la susceptibilidad al CaP en la población china Han. La posible asociación de rs8082134 de MPO con el riesgo de CaP necesita más aclaraciones.

Palabras clave:
Mieloperoxidasa
Polimorfismo
Cáncer de próstata
Susceptibilidad

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos